The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
